MCL Literature Feed

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

Consensus guidelines recommend the BOVen triplet (zanubrutinib, obinutuzumab, venetoclax) for TP53-mutated MCL and CAR-T for BTKi-refractory disease, providing expert guidance for managing high-risk patients.

This review outlines the evolving MCL treatment paradigm, detailing the integration of BTKi, CAR-T, and bispecific antibodies in both frontline and relapsed/refractory settings to improve patient outcomes.

Real-world data from Germany and Switzerland confirms the effectiveness of brexucabtagene-autoleucel in relapsed/refractory MCL, supporting its use in routine clinical practice beyond trial populations.

This review outlines evidence for sequencing BTKis, CAR-T, and bispecifics in relapsed/refractory MCL, a growing challenge as targeted therapies are increasingly used in the frontline setting.

This UK real-world study shows chemotherapy bridging before brexu-cel yields higher responses than targeted therapy but causes more toxicity and early mortality without improving post-CAR-T survival.

Brexucabtagene autoleucel demonstrates high efficacy (91% ORR, 73% CR) in BTKi-naive relapsed/refractory MCL, supporting its use as an effective option before BTKi failure in high-risk patients.

A novel single-cell technique, LiP-Seq, identified IFITM2 upregulation in rare persistent MCL cells post-CAR-T, revealing a new mechanism of immune evasion and a potential therapeutic target.

An expert panel opinion advocates for personalized MCL therapy, positioning BTKi as a frontline standard for transplant-ineligible patients and a potential alternative to consolidation transplant for others.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

Proteomic profiling identified an MCL-specific protein signature, including seven targets missed by RNA analysis, offering novel avenues for CAR-T therapy and personalized treatment.

Bridging radiotherapy before CAR-T effectively controls disease in MCL patients, with most showing rapid tumor reduction and no local progression, supporting its use as a pre-CAR-T strategy.

This real-world study identifies key patient and systemic barriers limiting CAR-T therapy access for relapsed/refractory MCL, highlighting disparities between trial eligibility and clinical practice.

This review provides a treatment and sequencing algorithm for relapsed/refractory MCL, navigating the complex landscape of BTKi, BCL2i, CAR-T, bispecifics, and transplant for individualized patient care.

The CD19 CAR-T therapy relma-cel demonstrated high, durable responses (71% ORR, 18-month DOR) with manageable toxicity in heavily pretreated Chinese patients, establishing it as an effective option for relapsed/refractory MCL.

In a retrospective ZUMA-2 analysis, prior ibrutinib exposure, versus acalabrutinib, improved brexu-cel CAR-T efficacy and PFS by inducing a more favorable cytotoxic T-cell phenotype.

This report summarizes the 2025 LRF MCL Workshop, highlighting key research developments in pathogenesis, resistance, and novel therapies, thereby setting the agenda for future clinical and translational research.

This review positions CAR-T and bispecific antibodies as complementary tools for relapsed/refractory MCL, advocating for individualized sequencing and combinations to optimize outcomes in heavily pretreated, high-risk patients.

This meta-analysis quantifies the high incidence of neurotoxicity (ICANS) with brexucabtagene autoleucel in MCL, finding 61% of patients experience any grade and 33% experience severe events.

In a real-world French cohort, MCL patients failing CAR-T therapy have dismal outcomes (median OS 5.8 months), highlighting an urgent need for effective salvage, with bispecific antibodies showing promise.

Emapalumab, an interferon-gamma blocker, successfully treated severe immune effector cell-associated HLH-like syndrome (IEC-HS) in a relapsed MCL patient post-CAR-T, offering a targeted approach for this life-threatening toxicity.

This review summarizes mechanisms of resistance and relapse after CAR-T/CAR-NK therapy, such as antigen loss and T-cell exhaustion, offering insights for improving durability in MCL.

This case report demonstrates CD19 downregulation as a key mechanism of resistance and subsequent relapse in a heavily pretreated MCL patient following initially effective CD19-targeted CAR-T therapy.

This case report describes an early-onset disseminated adenovirus infection after CAR-T therapy for relapsed/refractory MCL, highlighting a critical and potentially fatal infectious toxicity of this cellular therapy.

Brexucabtagene autoleucel induced a durable 19-month remission in heavily pretreated MCL with intraocular relapse, demonstrating CAR-T efficacy in this rare sanctuary site.

This preclinical study shows a SOX11 inhibitor overcomes BTKi, BCL2i, and CAR-T resistance by targeting the PAX5/CD19 axis, a novel upstream BCR signaling mechanism.

This case report details MCL transformation into CD19-negative classic Hodgkin lymphoma after CAR-T, a novel resistance mechanism driven by immunotherapeutic pressure and lineage plasticity in a high-risk patient.

This review summarizes the MCL treatment evolution from chemoimmunotherapy and transplant to targeted agents (BTKi) and immunotherapies (CAR-T, bispecifics), emphasizing a future of personalized, genomics-guided care.

A novel gene-editing method creates safer allogeneic CAR-T cells, potentially offering a more accessible 'off-the-shelf' cellular therapy option for MCL patients.

This review summarizes the rapid clinical integration of T-cell engaging therapies (CAR-T, bispecifics) for B-NHL, including MCL, and outlines future strategies like earlier use and novel constructs.